The United States Food and Drug Administration has officially granted approval to Scholar Rock for Isemblyd (apitegromab), establishing a monumental…
Read More
RNA breakthrough provides hope for thousands of untreatable diseases, including cystic fibrosis, muscular dystrophy and some cancers
A multi-institutional team of researchers at the University of Toronto has unveiled a next-generation RNA therapeutic platform designed to target…
Read More
Exegenesis Bio and Modalis Therapeutics Join Forces in Strategic Licensing Agreement to Advance MDL-201 Gene Therapy for Duchenne Muscular Dystrophy
In a significant development for the field of genetic medicine, biotechnology innovators Exegenesis Bio and Modalis Therapeutics have formally announced…
Read More
